ethyl 1-(5-tert-butoxycarbonylamino-2,4-difluorophenyl)-8-chloro-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate | 197520-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 1-(5-tert-butoxycarbonylamino-2,4-difluorophenyl)-8-chloro-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
• 英文别名: Ethyl 1-(5-tert-butoxycarbonylamino-2,4-difluorophenyl)-8-chloro-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate；ethyl 8-chloro-1-[2,4-difluoro-5-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-6,7-difluoro-4-oxoquinoline-3-carboxylate
• CAS: 197520-73-3
• 化学式: C₂₃H₁₉ClF₄N₂O₅
• 分子量: 514.861
• InChiKey: NPCARUGLWFHNLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ethyl 1-(5-tert-butoxycarbonylamino-2,4-difluorophenyl)-8-chloro-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 在 盐酸 、 溶剂黄146 作用下， 以85%的产率得到1-(5-amino-2,4-difluorophenyl)-8-chloro-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  Phenylenediamines and process for preparing the same

  摘要：

  通式(1)表示的苯二胺类化合物：##STR1## 其中，R代表烷基或可选择取代的芳基烷基，X.sup.1代表氢原子或卤素原子，X.sup.2代表卤素原子；其盐以及制备它们的方法。这些化合物可用作合成吡啶酮羧酸衍生物的中间体，这些衍生物可用作抗菌剂。

  公开号：

  US05994575A1
• 作为产物：
  描述：

  2,4-二氟苯甲酸 在 钯 sodium azide 、 草酰氯 、 硫酸 、 氢气 、 potassium carbonate 、 potassium nitrate 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 116.33h， 生成 ethyl 1-(5-tert-butoxycarbonylamino-2,4-difluorophenyl)-8-chloro-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  A Novel Antibacterial 8-Chloroquinolone with a Distorted Orientation of the N1-(5-Amino-2,4-difluorophenyl) Group

  摘要：

  Fluoroquinolones represent a major class of antibacterial agents with great therapeutic potential. In this study, we designed m-aminophenyl groups as novel N-1 substituents of naphthyridones and quinolones. Among newly synthesized compounds, 7-(3-aminoazetidin-1-yl)-1-(5-amino-2,4-difluorophenyl)-8-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4) has extremely potent antibacterial activities against Gram (+) as well as Gram (-) bacteria. This compound is significantly more potent than trovafloxacin against clinical isolates: 30 times against Streptococcus pneumoniae and 128 times against methicillin resistant Staphylococcus aureus. The structure-activity relationship (SAR) study revealed that a limited combination of 1-(5-amino-2,4-difluorophenyl) group, 7-(azetidin-1-yl) group, and 8-Cl atom (or Br atom or Me group) gave potent antibacterial activity. An X-ray crystallographic study of a 7-(3-ethylaminoazetidin-1-yl)-8-chloro derivative demonstrated that the N-1 aromatic group was remarkably distorted out of the core quinolone plane by steric repulsion between the C-8 C1 atom and the N-1 substituent. Furthermore, a molecular modeling study of 4 and its analogues demonstrated that a highly distorted orientation was induced by a steric hindrance of the C-8 substituent, such as Cl, Br, or a methyl group. Thus, their highly strained conformation should be a key factor for the potent antibacterial activity.

  DOI：

  10.1021/jm0205090

文献信息

• Pyridonecarboxylic acid derivatives or salts thereof and drugs
  申请人：Wakunaga Pharmaceutical Co., Ltd.

  公开号：US06136823A1

  公开（公告）日：2000-10-24

  The invention relates to pyridonecarboxylic acid derivatives represented by the general formula (1): ##STR1## wherein R.sup.1 is --OH, a carboxy-protecting group or (alkyl)amino group, R.sup.2 is H, or --NO.sub.2, (protected) amino, (protected) hydroxyl, lower alkyl or lower alkoxyl group, R.sup.3 is a halogen atom, H, or --NO.sub.2, lower alkyl, lower alkoxyl or amino group, R.sup.4 is an azido, (substituted) hydrazino, (substituted) amino, lower alkoxyl or hydroxyl group, R.sup.5, R.sup.6 and R.sup.7 are independently H, --NO.sub.2, halogen atom or lower alkyl group, R.sup.8 is a --NO.sub.2, (substituted) amino, --OH or lower alkoxyl group, A is N or C--R.sup.12, in which R.sup.12 is H, halogen atom, or (substituted) lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, lower alkylthio or nitro group, and B is N or C--R.sup.13, in which R.sup.13 is H or halogen atom, or salts thereof, and medicine comprising such a compound as an active ingredient. The derivatives or the salts thereof exhibit excellent antibacterial action and peroral absorbability, scarcely cause side effects, and are easy of synthesis.

  该发明涉及由通式（1）表示的吡啶酮羧酸衍生物：##STR1##其中R.sup.1为--OH、羧保护基团或（烷基）氨基团，R.sup.2为H或--NO.sub.2、（保护）氨基、（保护）羟基、较低烷基或较低烷氧基团，R.sup.3为卤素原子、H或--NO.sub.2、较低烷基、较低烷氧基或氨基团，R.sup.4为偶氮基、（取代）叠氮基、（取代）氨基、较低烷氧基或羟基团，R.sup.5、R.sup.6和R.sup.7独立地为H、--NO.sub.2、卤素原子或较低烷基团，R.sup.8为--NO.sub.2、（取代）氨基、--OH或较低烷氧基团，A为N或C--R.sup.12，其中R.sup.12为H、卤素原子或（取代）较低烷基、较低烯基、较低炔基、较低烷氧基、较低硫代烷基或硝基团，B为N或C--R.sup.13，其中R.sup.13为H或卤素原子，或其盐，以及包括此类化合物作为活性成分的药物。这些衍生物或其盐表现出优异的抗菌作用和口服吸收性，几乎不会引起副作用，并且易于合成。
• Phenylenediamines and process for preparing the same
  申请人：Wakunaga Pharmaceutical Co., Ltd.

  公开号：US05994575A1

  公开（公告）日：1999-11-30

  Phenylenediamines represented by general formula (1): ##STR1## wherein R represents an alkyl group or an optionally substituted aralkyl group, X.sup.1 represents a hydrogen atom or a halogen atom, and X.sup.2 represents a halogen atom; salts thereof, and a process for preparing the same. The compounds are useful as intermediates for synthesis of pyridonecarboxylic acid derivatives useful as antibacterial agents.

  通式(1)表示的苯二胺类化合物：##STR1## 其中，R代表烷基或可选择取代的芳基烷基，X.sup.1代表氢原子或卤素原子，X.sup.2代表卤素原子；其盐以及制备它们的方法。这些化合物可用作合成吡啶酮羧酸衍生物的中间体，这些衍生物可用作抗菌剂。
• NOVEL PHENYLENEDIAMINES AND PROCESS FOR PREPARING THE SAME
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：EP0897909A1

  公开（公告）日：1999-02-24

  Phenylenediamines represented by general formula (1): wherein R represents an alkyl group or an optionally substituted aralkyl group, X1 represents a hydrogen atom or a halogen atom, and X2 represents a halogen atom; salts thereof, and a process for preparing the same. The compounds are useful as intermediates for synthesis of pyridonecarboxylic acid derivatives useful as antibacterial agents.

  由通式(1)代表的苯二胺： 其中 R 代表烷基或任选取代的芳烷基，X1 代表氢原子或卤素原子，X2 代表卤素原子；它们的盐及其制备方法。这些化合物可用作合成可用作抗菌剂的吡啶甲酸衍生物的中间体。
• NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：EP0945435A1

  公开（公告）日：1999-09-29

  The invention relates to pyridonecarboxylic acid derivatives represented by the general formula (1): wherein R1 is -OH, a carboxy-protecting group or (alkyl)-amino group, R2 is H, or -NO2, (protected) amino, (protected) hydroxyl, lower alkyl or lower alkoxyl group, R3 is a halogen atom, H, or -NO2, lower alkyl, lower alkoxyl or amino group, R4 is an azido, (substituted) hydrazino, (substituted) amino, lower alkoxyl or hydroxyl group, R5, R6 and R7 are independently H, -NO2, halogen atom or lower alkyl group, R8 is a -NO2, (substituted) amino, -OH or lower alkoxyl group, A is N or C-R12, in which R12 is H, halogen atom, or (substituted) lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, lower alkylthio or nitro group, and B is N or C-R13, in which R13 is H or halogen atom, or salts thereof, and medicine comprising such a compound as an active ingredient. The derivatives or the salts thereof exhibit excellent antibacterial action and peroral absorbability, scarcely cause side effects, and are easy of synthesis.

  本发明涉及通式（1）所代表的吡啶甲酸衍生物： 其中 R1 是-OH、羧基保护基团或（烷基）-氨基；R2 是 H、或-NO2、（保护）氨基、（保护）羟基、低级烷基或低级烷氧基；R3 是卤素原子、H、或-NO2、低级烷基、低级烷氧基或氨基；R4 是叠氮基、（取代的）肼基、（取代的）氨基、低级烷氧基或羟基；R5、R6 和 R7 独立地是 H、-NO2、A是N或C-R12，其中R12是H、卤素原子或（取代的）低级烷基、低级烯基、低级炔基、低级烷氧基、低级烷硫基或硝基，B是N或C-R13，其中R13是H或卤素原子，或其盐，以及包含此类化合物作为活性成分的药物。这些衍生物或其盐具有出色的抗菌作用和口腔吸收性，几乎不会产生副作用，而且易于合成。
• US5994575A
  申请人：——

  公开号：US5994575A

  公开（公告）日：1999-11-30